ClinicalTrials.gg
RecruitingNCT06295328HepBTerUpdated Feb 7, 2025

From Fungus to Virus, Investigating the Safety and Efficacy of Terbinafine in Chronic Hepatitis B Patients

A Phase 1/2 interventional study of Terbinafine and Placebo in Chronic Hepatitis B, sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA). Recruiting at 1 site in Netherlands. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-02-07.

Sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Apr 2025, 1 year 7 months ago, but the record still lists the study as recruiting.
  • Registered 1 year 9 months after the study started (first participant enrolled Apr 2022, registered Feb 2024).
  • Started Apr 2022; still recruiting 4 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 19 studies in Hepatitis B, Chronic with a site in Netherlands — 1 open to participants now, 2 under way, none of them phase 3. Hepatitis B, Chronic · Netherlands.

Planned enrollment
12th of 16
36 · median 117
Started
2022
with 1 other
Phase 1/2
3 of 19
1 open now
Registered
19th of 19
by date
Lead sponsor
2 of 19
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Among the 19 studies in Hepatitis B, Chronic with a site in Netherlands, this one is the 12th largest by planned enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2022, is one of 3 in phase 1/2, and was the 19th registered.

Hepatitis B, Chronic

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

1 of the 19 studies in Hepatitis B, Chronic with a site in Netherlands is open now.

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Hepatitis B, Chronic with a site in Netherlands, or all of them as a file.
02

Study summary

Rationale: Currently, there is no curative therapy available for patients that are chronically infected with the hepatitis B virus (HBV). Especially the presence of a viral reservoir of stable episomal, covalently closed circular DNA (cccDNA) in the nucleus of infected hepatocytes poses a great challenge for the development of curative therapies. HBV cccDNA acts as the template for production of viral proteins and HBV genomes. In a preclinical study, terbinafine (an antifungal agent) was identified as a potent and specific suppressor of HBx-mediated cccDNA transcription. HBx is an accessory viral protein of HBV which has been proven to be essential for HBV replication and enhances replication at the transcriptional level in vivo. The suppression of cccDNA transcription results in a strong reduction of the production of viral genomes (RNA and DNA) as well as viral proteins. This will allow recovery of the immune system, increase viral clearance and prevent replenishment of the cccDNA pool in the hepatocyte, all contributing to cure chronic hepatitis B (CHB).

Objective: to provide proof of concept for the inhibition of HBx mediated cccDNA transcription by terbinafine, both as monotherapy and add-on therapy next to tenofovir. Secondary outcomes will be the safety and tolerability of terbinafine in this specific group.

Study design: This pilot study is a stratified, single center, randomized, double-blinded, placebo-controlled, dose-ascending proof of concept clinical trial.

Study population: patients chronically infected with the hepatitis B virus with a normal liver function and no signs of liver damage, who do not use any antiviral medication (group A, n=16) or are treated with tenofovir > 6 months (group B, n=16).

Intervention: Patients will be randomly allocated to daily oral treatment with terbinafine or a matched placebo, either as monotherapy (group A) or as add-on therapy to tenofovir (group B).

Main study parameters/endpoints: Primary outcomes: decline in level of serum HBsAg >0.32log10 IU/mL in both groups A and B and decline in serum HBV DNA >0.86log10 in group A at the end of study treatment (week 10 vs baseline). Secondary outcomes: 1) Safety and tolerability of terbinafine as mono- or combination therapy; 2) level of serum HBsAg and HBV DNA at 3 months follow-up; 3) decline of HBsAg levels over time (all visits); 4) HBV RNA, large HBsAg (LHBs) HBcrAg levels, and HBeAg status at baseline and end of study 4).

Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Patients participating in this study will undergo physical examinations and blood sample collections (13 samples and in total 467.5 mL). They will also be asked to fill in the HBQOL and EQ5D5L quality of life questionnaires and a medicine diary. In total there will be 13 visits in the hospital of which 7 will be for blood collection only. Terbinafine can induce liver damage 1 of 50,000 to 120,000 prescriptions (LiverTox), a weekly safety laboratory control is implemented in the visits to detect possible liver toxicity in an early stage and prevent liver damage.

03

Conditions studied

  • Chronic Hepatitis B

Browse trials for

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18 - 60 years
  2. Proven CHB for more than 6 months, based on serology ( positivity) and at screening a viral load of:

    i) Group A: HBV DNA ≥200 IU/mL and \<20,000 IU/mL ii) Group B: HBV DNA \< 20 IU/mL

  3. HBeAg-positive or HBeAg-negative
  4. No current use of any antiviral medication (group A) or currently treated with tenofovir only, for > 6 months (group B).
  5. Normal liver function tests, assessed as follows:

    i) Liver stiffness measurement using Fibroscan® of ≤ 7.0 kiloPascal (kPa) ii) (ALT) and/or aspirate aminotransferase (AST) at screening ≤ 1.25 x (ULN) iii) 150-400 10E9/L iv) Total 0-17 µmol/L (elevated levels may be accepted if unconjugated portion is elevated in patients with Gilbert syndrome) v) Albumin within normal value (35 - 50 g/L) vi) (PT) within normal value (9,5 - 12.5 sec) vii) Alkaline phosphatase (ALP) and Gamma-glutamyltransferase (GGT) within normal values (40-120 U/L and 0-40 U/L respectively)

  6. (BMI): 17.0-35.0 kg/m2
  7. Clinical chemistry, hematologic and coagulation tests at screening must be within normal limits or clinically non-significant, as by the investigator's assessment.
  8. At screening, women of child bearing potential must be non-pregnant and non-lactating; a urine or serum pregnancy test will be performed at screening.
  9. Female patients of (with a fertile male sexual partner) and male patients (if not surgically sterilized) must be willing to use adequate from screening until last study visit.
  10. No recent (\<3 months) history of any conditions, which, in the opinion of the investigator, would jeopardize the safety of the patient or impact the validity of the study results.
  11. Written must be obtained before any study related interventions (including screening and enrollment) can be conducted.

Exclusion criteria

Exclusion Criteria:

  1. Currently active, or a history of liver cirrhosis determined by one or more of the following:

    i) Liver ; ii) Elastography (e.g. Fibroscan); iii) Combination of usual radiological and biochemical criteria

  2. Currently active liver disease other than CHB
  3. Co-infection with virus (HCV), hepatitis D virus (HDV), hepatitis E virus (HEV) and/or (HIV)
  4. Acute hepatitis A virus (HAV) infection at screening
  5. Renal impairment (estimated (eGRF) \< 60ml/min)
  6. Currently active, or a history of, psoriasis or lupus erythematodes
  7. Use of oral medication that interacts with the liver metabolism enzyme CYP2D6, or which is known to be hepatotoxic or otherwise known to interact with terbinafine (such as rifampicin).
  8. The use of a L-type calcium (LTCC) blocker (such as lomerizine of nifedipine), since these may interact with the transcription according to the article by Klundert et al.
  9. Usage or plans to receive systemic or immunomodulating medication (e.g. IFN) during the study or ≤4 months prior to the first product administration.
  10. Clinical diagnosis of substance abuse ≤12 months prior to screening with narcotics or cocaine or with alcohol (regular consumption >14 units/week [men] and >7 units/week [women])
  11. Inability to understand the patient information and make an informed decision to participate
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
36 participants (estimated)

Study arms

  • Active comparator
    NUC + Study drug

    Tenofovir + Terbinafine

    Drug: Terbinafine · Drug: Tenofovir

  • Placebo comparator
    NUC + Placebo

    Tenofovir + Placebo

    Drug: Placebo · Drug: Tenofovir

  • Active comparator
    Study drug

    Terbinafine

    Drug: Terbinafine

  • Placebo comparator
    Placebo

    Placebo

    Drug: Placebo

Interventions

  • terbinafine 250mg once daily for 4 weeks, followed by 2 weeks washout, followed by 4 weeks bid.

  • DrugPlacebo

    Placebo 250mg once daily for 4 weeks, followed by 2 weeks washout, followed by 4 weeks bid.

  • Tenofovir 245mg standard of care

06

What researchers measure

Primary outcomes

  1. Change in level of serum HBsAG

    - Change in level of serum HBsAg \>0.32 log10 IU/mL at the end of study treatment (week 10 vs baseline).

    Time frame: 10 weeks

  2. Change in serum HBV DNA

    - Change in serum HBV DNA \>0.86 log10 in group A (monotherapy) at the end of study treatment (week 10 vs baseline).

    Time frame: 10 weeks

Secondary outcomes

  1. Safety of terbinafine

    - Safety of terbinafine as mono- or combination therapy, as defined by the number of patients with treatment-related laboratory adverse events as assessed by CTCAE v4.0.

    Time frame: 10 weeks

  2. Tolerability of terbinafine

    - Tolerability of terbinafine as mono- or combination therapy, as defined by the number of patients with treatment-related adverse events as assessed by CTCAE v4.0

    Time frame: 10 weeks

  3. Serum levels of HBsAG

    - Level of serum (large) HBsAg at 3 months follow-up.

    Time frame: 3 months

  4. Serum levels of HBV DNA

    - Level of serum HBV DNA at 3 months follow-up.

    Time frame: 3 months

  5. Serum levels of HBV RNA

    - Level of serum HBV RNA at 3 months follow-up.

    Time frame: 3 months

  6. Serum levels of HBcrAg

    - Level of serum HBcrAg at 3 months follow-up.

    Time frame: 3 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2022 (actual). Primary completion is estimated for Apr 2025, 35 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2024
First posted
Mar 6, 2024
StartActual
Apr 13, 2022
Primary completionEst.
Apr 1, 2025
CompletionEst.
Apr 1, 2025
Last update
Feb 7, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06295328
Responsible party
Ulrich Beuers (Prof. Dr., Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)) — Principal investigator
First posted
Mar 6, 2024
Start date
Apr 13, 2022
Primary completion
Apr 1, 2025 (estimated)
Completion
Apr 1, 2025 (estimated)
Last update
Feb 7, 2025

Study contacts

U. Beuers, Prof. Dr.
Contact
u.h.beuers@amsterdamumc.nl
+31205662422
D.J. van Doorn, MD
Contact
d.j.vandoorn@amsterdamumc.nl
+31207329491

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Terbinafine

Start the discussion